GIM
HBIO icon

Granahan Investment Management’s Harvard Bioscience HBIO Stock Holding History

Granahan Investment Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60,352
Closed -$265K – 163
2025
Q3 		$265K Sell
60,352
-89,799
-60% -$426K 0.01% 145
2025
Q2 		$666K Sell
150,151
-2,638
-2% -$11K 0.03% 147
2025
Q1 		$865K Sell
152,789
-8,929
-6% -$114K 0.04% 144
2024
Q4 		$3.41M Sell
161,718
-24,825
-13% -$570K 0.14% 131
2024
Q3 		$5.02M Sell
186,543
-5,997
-3% -$177K 0.2% 129
2024
Q2 		$5.49M Buy
192,540
+6,165
+3% +$216K 0.22% 120
2024
Q1 		$7.9M Buy
186,375
+2,027
+1% +$91.1K 0.28% 100
2023
Q4 		$9.86M Buy
184,348
+10,791
+6% +$487K 0.33% 90
2023
Q3 		$7.46M Buy
173,557
+29,612
+21% +$1.37M 0.27% 104
2023
Q2 		$7.9M Buy
143,945
+930
+0.7% +$51K 0.24% 104
2023
Q1 		$6.01M Sell
143,015
-3,231
-2% -$95.8K 0.18% 114
2022
Q4 		$4.05M Sell
146,246
-3,081
-2% -$75.9K 0.12% 142
2022
Q3 		$3.82M Sell
149,327
-3,942
-3% -$130K 0.12% 141
2022
Q2 		$5.52M Buy
153,269
+7,594
+5% +$343K 0.19% 113
2022
Q1 		$9.05M Sell
145,675
-20,107
-12% -$1.19M 0.22% 99
2021
Q4 		$11.7M Buy
165,782
+7,816
+5% +$556K 0.24% 105
2021
Q3 		$11M Buy
157,966
+4,010
+3% +$319K 0.21% 107
2021
Q2 		$12.8M Buy
153,956
+2,024
+1% +$143K 0.24% 96
2021
Q1 		$8.3M Sell
151,932
-403
-0.3% -$19.6K 0.18% 105
2020
Q4 		$6.54M Sell
152,335
-23,383
-13% -$873K 0.15% 116
2020
Q3 		$5.29M Buy
175,718
+2,404
+1% +$80.8K 0.18% 102
2020
Q2 		$5.37M Sell
173,314
-11,301
-6% -$304K 0.19% 104
2020
Q1 		$4.08M Sell
184,615
-3,868
-2% -$105K 0.22% 94
2019
Q4 		$5.75M Buy
188,483
+11,287
+6% +$325K 0.26% 86
2019
Q3 		$5.45M Buy
177,196
+84,819
+92% +$2.11M 0.3% 80
2019
Q2 		$1.85M Sell
92,377
-6,293
-6% -$184K 0.09% 146
2019
Q1 		$4.25M Sell
98,670
-10,498
-10% -$381K 0.23% 108
2018
Q4 		$3.47M Sell
109,168
-2,281
-2% -$89.9K 0.25% 99
2018
Q3 		$5.85M Buy
111,449
+3,913
+4% +$220K 0.32% 90
2018
Q2 		$5.75M Buy
107,536
+11,371
+12% +$582K 0.35% 91
2018
Q1 		$4.81M Buy
96,165
+2,593
+3% +$116K 0.35% 94
2017
Q4 		$3.09M Buy
93,572
+39,825
+74% +$1.34M 0.24% 120
2017
Q3 		$2.02M Buy
53,747
+24,006
+81% +$710K 0.17% 137
2017
Q2 		$758K Sell
29,741
-71,832
-71% -$1.78M 0.07% 159
2017
Q1 		$2.64M Sell
101,573
-52,209
-34% -$1.5M 0.27% 111
2016
Q4 		$4.69M Buy
153,782
+21,670
+16% +$551K 0.16% 151
2016
Q3 		$3.59M Buy
132,112
+3,439
+3% +$95.5K 0.12% 165
2016
Q2 		$3.68M Sell
128,673
-5,507
-4% -$175K 0.13% 163
2016
Q1 		$4.05M Sell
134,180
-7,142
-5% -$202K 0.15% 169
2015
Q4 		$4.9M Sell
141,322
-28,983
-17% -$991K 0.17% 167
2015
Q3 		$6.44M Sell
170,305
-4,890
-3% -$228K 0.2% 159
2015
Q2 		$9.99M Buy
175,195
+12,531
+8% +$713K 0.28% 127
2015
Q1 		$9.47M Sell
162,664
-1,564
-1% -$84K 0.27% 134
2014
Q4 		$9.31M Sell
164,228
-231
-0.1% -$11K 0.27% 122
2014
Q3 		$6.73M Sell
164,459
-6,363
-4% -$293K 0.21% 146
2014
Q2 		$7.77M Sell
170,822
-4,770
-3% -$200K 0.23% 143
2014
Q1 		$8.32M Buy
175,592
+3,196
+2% +$145K 0.22% 148
2013
Q4 		$8.1M Buy
172,396
+39,266
+29% +$1.72M 0.21% 149
2013
Q3 		$5.31M Buy
133,130
+3,828
+3% +$151K 0.14% 168
2013
Q2 		$4.61M Buy
+129,302
New +$4.95M 0.13% 173

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Granahan Investment Management's HBIO Position: Q4 2025 in Review

Granahan Investment Management sold out of Harvard Bioscience (HBIO) in Q4 2025, closing a stake of 60,352 shares — an estimated $265K sold.

Granahan Investment Management first reported a position in HBIO in Q2 2013 and held it in 50 quarters. The position peaked at $12.8M in Q2 2021. 63 funds tracked by Wall St. Rank hold HBIO as of Q4 2025.

  • Granahan Investment Management reported no remaining Harvard Bioscience position as of Q4 2025 after selling out during the quarter.
  • Granahan Investment Management sold 60,352 Harvard Bioscience shares in Q4 2025, an estimated $265K.
  • Granahan Investment Management first reported a position in Harvard Bioscience in Q2 2013 and held it in 50 quarters.
  • Granahan Investment Management's Harvard Bioscience position peaked at $12.8M in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2025.

Based on Granahan Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.